3^rd World Conference on Pharmaceutical Research and Drug Management December 03-04, 2020 Paris, France

Drug Discovery may be a branch in pharmacy during which invention of potent drug entities is that the important role to be involved. The major part of drug design involves the identification of characteristic diagnostic biomarkers such as a protein responsible for the disease or disorder and then developing a drug molecule of therapeutic potency that targets it. The process involves various branches of pharmacology coalesce with biotechnology, bioinformatics, molecular biology, nanotechnology and biochemistry that ultimately leads to the production of molecules of therapeutic value. Despite the advancements in modern technologies and an understanding of the biological systems, the drug discovery process is still a lengthy and expensive task. There are only a few therapeutic drugs that pass the test and enter the market but today's accelerated studies using computational drug design techniques speed up the process of drug discovery.

• Diagnostic markers as therapeutic targets
• Approaches in target identification and validation
• In silico pharmacology
• Drug design and molecular modeling
• Molecular docking studies

Pharmaceutical Delivery Technologies are mainly focused on enhancing the drug absorption, patient experience and efficacy of Drug. Bioavailability of medicines within the system is often achieved by increasing the dissolution rate with specialized drug delivery enhancement products. By increasing the latest Technologies for Drug-delivery it is possible to increase its commercial success. The main routes of drug delivery are oral, injection/infusion, and transdermal. Drug-eluting stents and other implantable drug delivery devices are presented, as well as externally applied devices. When combined with appropriate targeting moieties, drug-coated nanoparticles, drug-encapsulating liposomes and nanotubes, and tree-like dendrimers enable organ and tissue targeting.

In the recent years we can see the rapid spread of nanotechnology in the field of medicine and seen in various aspects of drug delivery. In present scenario various substances are under investigation for the therapy of drug delivery and mostly concentrated on cancer therapy. And as a recent improvement, pharmaceutical sciences use nanoparticles in order to decrease the side effects of drugs and even up to did not realize the carrier system that is impose to risk to the patient.

The kind of hazards that are introduced by using nanoparticles for drug delivery are beyond that posed by conventional hazards imposed by chemicals in classical delivery matrices

Nanotechnology has now introduced to develop medicine. Nanotechnology contains the use of materials with essential length scales in the nanometer measurement which demonstrate significantly changed properties associated to micron structured materials. Such materials can include particles, fibers, grain sizes, etc. This session highlighted the progression nanotechnology is making in medicine in such fields as disease prevention, diagnosis, and treatment including (but not limited to) drug delivery, tissue engineering, implants, sensors, cancer treatment an (but not limited to) drug delivery, transplants, tissue engineering, and toxic.

The latest drug discovery system brings many advancements and developments in the new drugs. Now a days new biological targets, methodologies and advanced computing have enhanced modern drug discovery and have given medicinal chemistry a more thoughtful skill set and toolkit to hold the nuances  of disease pathophysiology. The mixture of both medicinal chemistry and methodology in drug discovery together makes drug delivery more efficient and more lessening attrition. In drug designing, structure-based drug design, and fragment –based drug design, natural product-based drug design, diversity-based drug design, and chemo genomics are applied.

As we observe in the recent days, it is seen that nanotechnology has become the most significant interest to the wide range of area in pharmaceutical industry. Nanomaterials have been used in-vivo preclinical and clinical trials. The selection of a particular techniques or methods is based on administration routes, dose, drug target, drug physicochemical properties, target cells or tissues. All diverse nano sized structures has been investigated in order to get drug delivery and drug formulations. The nano-sized crystalline drug, drug-polymer and drug-antibody conjugates, dendrimers, liposomes, lipid emulsions, and solid drug-polymer nanoparticle dispersions are some of the drug carriers containing nanomaterial.

• 
  Therapeutic properties of nanomaterials


• 
  Nanoparticles as drug vehicles


• 
  Role of nanotechnology in drug design and manufacture


• 
  Biocompatibility of nanoparticles


• 
  Regenerative Therapeutics

As our focus is on major challenges of drug delivery in drug delivery technology industry. The sessions included in this are Reducing Patient Compliance, overcoming challenges in pediatric drug delivery, Drug Delivery of poorly soluble drugs, Polymeric enhancement as the drug delivery system, controlling the addictive nature of drugs. The demand for non-invasive drug delivery is increasing effectively, ideally and non-invasive drug delivery methods. The overwhelming growth in the case of biopharmaceutical sector is seen due to the advances in biotechnology. As we see in 2009, over $12 billion were invested in biologics and biotechnology research and development (R&D), which is contributing a 26% share in the total R&D expenditure. As the recent report takes that Pharmaceutical Research and Manufacturers of America (PhRMA) in 2015, there are nearly 901 biologicals in development, targeting more than 100 diseases.

The processes of designing a replacement drug by using bioinformatics implements have opened a replacement area of drug research and development. Computational techniques assist us in searching various drug targets and in Drug-Formulation designing drug.

Drug Discovery 2020 and bioinformatics affects drug formulation and new drug design in the fallowing drug design path.

By using computational methods and the 3D structural information of the protein target, we are now able to scrutinize the detailed underlying molecular and atomic interactions involved in ligand: protein interactions and thus interpret experimental results in detail. The use of computers in drug formulation and drug discovery bears the additional advantage of delivering new drug candidates more rapidly and cost-efficiently. Computer-aided drug discovery has recently had important successes in drug formulation: new ligands have been predicted along with their receptor-bound structures and in several circumstances the achieved hit rates (ligands discovered per molecules tested) are significantly greater than through experimental high-throughput screening.

Targeted drug delivery systems are the way to deliver the payload to the desired site of action without the interaction with normal cells. The number of targeted drug delivery systems like use of microfluidics, nanoparticle-based formulations and the use of monoclonal antibodies for anticancer drugs are in the market and many more are in research phase. Successful translations of potential cancer, gene therapies and particularly small interfering RNA delivery (siRNA) will largely depends on targeted drug delivery strategies. In future, the advancements in these approaches can reach to significant improvements in cancer therapy procedures to avoid risks associate with chemotherapy in these methodologies.

Cardiovascular diseases are projected to affect populace across the world. Cardiovascular diseases contain diseases and disorders related to heart and blood vessels. Numerous drugs are accessible and are under development for treating cardiovascular diseases based on various signs such as arrhythmia, myocardial infarction, and atherosclerosis. The global range of cardiovascular drug has been involved into many varieties of drugs. Some of the main cardiovascular drugs include anti-hypertensive drugs like calcium channel blockers and angiotensin II receptor antagonists, and hypolipidemic drugs.

In this session we will focus on Medical Devices designed for drug delivery through the pulmonary and nasal routes. These routes are of interest for local delivery, as in asthma, but also for rapid delivery of medicine to the system circulation and direct delivery to the central systema nervosum. The specific anatomical and psychological accounted intranasal and pulmonary routes will only be featured. Drug delivery devices are the specific tools that are used for delivering of a drug via specific route of administration. Such devices are used as part of one or more medical treatments. As many of the industries felt that it is unnecessary to feel this health care as a complex problem and so it delays in maintaining the better health care. But as it is needful to change that perception, last year FDA announces around $40 million to a new Medical Device Innovation Consortium (MDIC) that is charged with simplifying the process of designing and testing the new technologies. With the input taken from industry, government and some non-profit organizations along with some public private MDIC will prioritize the regulatory science needs of the community and fund rising projects to streamline the process easily.

Current research on femtosecond laser micro fabrication of fluidic devices is introduced to present their research to elaborate. The research areas on microfluidics provide a good range of sensitive microfluidic sensors for practical applications with the added advantage of low-cost portability, efficiency, sensitivity and versatility.